139 related articles for article (PubMed ID: 17347871)
1. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Beumer JH; Garner RC; Cohen MB; Galbraith S; Duncan GF; Griffin T; Beijnen JH; Schellens JH
Invest New Drugs; 2007 Aug; 25(4):327-34. PubMed ID: 17347871
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).
Cömezoğlu SN; Ly VT; Zhang D; Humphreys WG; Bonacorsi SJ; Everett DW; Cohen MB; Gan J; Beumer JH; Beijnen JH; Schellens HM; Lappin G
Drug Metab Pharmacokinet; 2009; 24(6):511-22. PubMed ID: 20045986
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra) in human plasma: method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants.
Xu XS; Zeng J; Mylott W; Arnold M; Waltrip J; Iacono L; Mariannino T; Stouffer B
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Feb; 878(5-6):525-37. PubMed ID: 20083444
[TBL] [Abstract][Full Text] [Related]
4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
6. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of patupilone in patients with advanced solid tumor malignancies.
Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
10. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and excretion of
van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of [
Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
[TBL] [Abstract][Full Text] [Related]
15. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
17. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
18. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
20. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Lee JJ; Seraj J; Yoshida K; Mizuguchi H; Strychor S; Fiejdasz J; Faulkner T; Parise RA; Fawcett P; Pollice L; Mason S; Hague J; Croft M; Nugteren J; Tedder C; Sun W; Chu E; Beumer JH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):515-26. PubMed ID: 26787503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
